Atopic Dermatitis: A hotspot for innovation and investment opportunities, says GlobalData
With the growth in AD, investment opportunities seem to be exciting, and pharmaceutical companies could invest in the R&D of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dupixent
EMA approval of Sanofi/Regeneron’s Dupixent fills biologic gap in COPD: GlobalData
Dupixent shows promise for COPD, new treatment option reduces flare - ups and improves breathing
Madrigal’s efforts for resmetirom will set tone for future launches of NASH therapies: GlobalData
In December 2022, the company successfully concluded raising a total of $309 million following positive topline data from the…
Dupixent (dupilumab) gets DCGI approval to treat moderate-to-severe atopic dermatitis
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement
Sanofi sees faster profit growth on Dupixent, flu vaccine
Sanofi reported a 26.5 per cent rise in third-quarter business operating income, or adjusted earnings before interest and tax, to…
US FDA accepts Dupixent for priority review in adults with prurigo nodularis
If approved, Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the US
Sanofi’s Dupixent wins US approval for bigger use
Sanofi's regulatory filing for EoE is under review by the European Medicines Agency (EMA)
Sanofi and Regeneron get EU approval for Dupixent
European Commission has extended marketing authorisation for Dupixent European Union to include adolescents 12 to 17 years of age…